Erwinase® and Erwinaze® are identical products developed and manufactured by PBL from the native organism Erwinia chrysanthemi. Erwinaze® is the brand name in the U.S.
Erwinase® remains globally available, and PBL is committed to all patients worldwide and will continue to support and ensure ongoing patient supply in accordance with applicable national regulations.
PBL has requested marketing approval of a Biologics Licence Application (BLA) for Erwinaze® which is currently under FDA review. This is necessary because PBL’s prior commercial partner has voluntairly revoked its prior BLA for Erwinaze® and is therefore no longer marketing Erwinaze®.
For any medical enquiries in relation to Erwinase® / Erwinaze® please contract PBL via email email@example.com